pan-Canadian Pharmaceutical Alliance (pCPA): February 2020 Trends and Insights Due to the COVID-19 outbreak, the pCPA is implementing measures to work within the current reality while still attempting to meet its mandate. Consequently, some existing negotiations may be delayed or temporarily halted while the negotiating jurisdiction focuses on responding to the COVID-19 situation. The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the February 29, … Read More →
MORSE Consulting Strengthens HTA Strategy and Payer Expertise
Toronto, February 18, 2020 – MORSE Consulting is pleased to expand and strengthen our service offering with the addition of Anita Carrie and Roy Cairns. Affordability of effective and innovative medications within the current Canadian public funding model is becoming very challenging for the healthcare system. Increasing budgetary constraints coupled with complex treatments requiring consideration of different sources and levels of evidence are an … Read More →
pCPA Closing in on 300 Completed Negotiations
pan-Canadian Pharmaceutical Alliance (pCPA): January 2020 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the January 31, 2020 status of brand negotiations. Highlights since the last update include: ● 2 products completed CADTH review, for a total of 9 files under consideration; ● 4 products initiated pCPA negotiations, for a total of 34 active negotiations; ● 2 negotiations completed for a … Read More →
MORSE Consulting Releases its Third Annual pCPA Year in Review Infographic (2019 Edition)
MORSE Consulting is pleased to release our Third Annual pCPA Year in Review infographic – 2019 Edition. This resource is aimed at helping market access stakeholders understand the top-line pCPA highlights from 2019. This infographic compares year-over-year metrics including: pCPA activity summary; average time to complete a negotiation; files adjudicated by the pCPA; and average negotiation duration by source. This infographic is an excerpt from the 2019 update … Read More →
A Busy 2019 ends with a quiet December
pan-Canadian Pharmaceutical Alliance (pCPA): December 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the December 31, 2019 status of brand negotiations. Highlights since the last update include: 3 products completed CADTH review, for a total of 10 files under consideration; 0 products initiated pCPA negotiations, for a total of 32 active negotiations; 1 negotiation completed for a total of 295 … Read More →
Season’s Greetings from MORSE Consulting
Happy Holidays from MORSE Consulting! As we enter the holiday season and the close of MORSE’s third year of operation, we wish to express our heartfelt gratitude to the Pharmaceutical Market Access community. We wish you a safe, peaceful, and enjoyable holiday season and the very best for 2020! — Read More →
Number of active negotiations (34) at lowest point since March 2017
pan-Canadian Pharmaceutical Alliance (pCPA): November 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the November 30, 2019 status of brand negotiations. Highlights since the last update include: 6 products completed CADTH review, for a total of 9 files under consideration; 4 products initiated pCPA negotiations, for a total of 34 active negotiations; 12 negotiations completed for a total of 294 … Read More →
Summary of the CADTH Drug Portfolio Information Session November 2019
Summary of CADTH Drug Portfolio Information Session Date: Monday, November 25, 2019 Time: 1:30 pm to 4:00 pm On November 25, 2019, CADTH hosted two information sessions in Toronto, Ontario for their Medical Device and Drug Portfolios. These annual sessions are an opportunity for stakeholders to get the latest information about priority initiatives and process changes. The summary below is separated into the … Read More →
RWE and OBA Working Group 2019 Findings & Executive Summary
The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.
The workload at pCPA appears to have stabilized over 2019
pan-Canadian Pharmaceutical Alliance (pCPA): October 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the October 31, 2019 status of brand negotiations. Highlights since the last update include: 4 products completed CADTH review, for a total of 7 files under consideration; 2 products initiated pCPA negotiations, for a total of 42 active negotiations; 6 negotiations completed for a total of 282 … Read More →
Update on the CanREValue Collaboration
Development of a framework for the generation and use of Real-World Evidence for cancer drug funding. The CanREValue Collaboration hosted a webinar on November 6, 2019 to introduce their preliminary framework and to outline the Stakeholder Feedback process. The slide deck that was presented, along with a recording can be accessed from the CanREValue website. The purpose of the CanReValue Collaboration is to … Read More →
Average Time Under pCPA Consideration Below 30 Days for the 3rd Consecutive Month
pan-Canadian Pharmaceutical Alliance (pCPA): September 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the September 30, 2019 status of brand negotiations. Highlights since the last update include: 4 products completed CADTH review, for a total of 6 files under consideration; 8 products initiated pCPA negotiations, for a total of 48 active negotiations; 6 negotiations completed for a total of 276 … Read More →
NEW Canadian Reimbursement Trends and Timelines Report – now available!
Toronto, September 18, 2019 – MORSE Consulting is pleased to launch the Canadian Reimbursement Trends and Timelines report – a comprehensive, credible and relevant source of market access intelligence. The market access pathway in Canada is going through an unprecedented level of change and uncertainty. This 58-page PowerPoint report is aimed at not only helping market access professionals plan for future launches but can … Read More →
15 Oncology Files either Completed, Initiated or new Under Consideration
pan-Canadian Pharmaceutical Alliance (pCPA): August 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the August 31, 2019 status of brand negotiations. Highlights since the last update include: 5 products completed CADTH review, for a total of 13 files under consideration; 8 products initiated pCPA negotiations, for a total of 47 active negotiations; 7 negotiations completed for a total of 270 … Read More →
Potential Impact of PMPRB Changes from a Regulatory, HTA and Payer Perspective
Introduction MORSE Consulting is pleased to contribute its pCPA/public payer expertise with leading pricing and reimbursement experts and provide our respective views on how the new PMPRB regulations may impact the Canadian environment. These experts include: PMPRB: Joan McCormick, Principal Consultant – IQVIA HTA/Health Economics (HE): Sumeet Singh & Heather Cameron – Cornerstone Research Group Inc. Private Payers: Suzanne Lepage, Suzanne Lepage Consulting The … Read More →
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2020 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
MORSE Market Access Signals - Latest in Pharmaceutical Reimbursement
